In July 2022, we have identified the following collaborations that caught our attention from the diagnostics perspective. Check them out:
1. Boehringer takes on antimicrobial resistance with Evotec, bioMérieux JV
A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections.
2. SD Biosensor agrees to buy Meridian Bioscience for $1.53B in bid to enter U.S. IVD market
SD Biosensor and SJL Partners agreed to acquire Meridian Bioscience in an all-cash deal valued at about $1.53 billion, according to a statement by Cincinnati-based Meridian on Thursday
3. Epic, Caris Life Sciences working together on molecular testing integration
Caris Life Sciences announced this week that it will be broadening its partnership with Epic, integrating its molecular testing portfolio with Epic's Orders and Results Anywhere network.
4. Illumina Invests in UK-Based Genomics Venture Fund Tied to Startup Accelerator Program
Illumina said on Tuesday that it has invested an undisclosed amount in Time Boost Capital, a genomics venture fund that plans to match funding raised by startups participating in the UK-based version of Illumina's accelerator program.
5. Boehringer Ingelheim, BiomX Embark on New Inflammatory Bowel Disease Biomarker Discovery Project
BiomX said Tuesday that it has inked a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease
6. Wayra joins AstraZeneca as an Innovation Partner to promote innovative initiatives in the health sector
Through this alliance, Wayra will provide AstraZeneca with access to the entrepreneurial ecosystem and its network of investors while identifying startups whose solutions can be applied to the main health challenges to which the pharmaceutical company wants to contribute. The companies will be able to test their solutions in real environments, with a special focus on the areas of oncology, cardiovascular, renal and metabolic, respiratory, and vaccines and immunotherapies.
7. MultiOmic Health, Mesh Bio Partner to Study Chronic Metabolic Disease for Drug, Dx Development
UK drug discovery company MultiOmic Health and Singapore-based predictive analytics startup Mesh Bio said Thursday that they are collaborating to apply artificial intelligence to improve diagnostics and advance drug discovery in chronic metabolic disease
8. Merck launches accelerator programme for AI startups
Merck & Co is looking for startup companies applying artificial intelligence , machine-learning and other digital approaches to drug discovery and development for a new accelerator programme.
9. Medtronic partners with CathWorks to work on CAD diagnosis and treatment
Medtronic has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel, which aims to transform how coronary artery disease (CAD) is diagnosed and treated.
10. Ultima Genomics, Regeneron Pharmaceuticals Ink Development Agreement
Sequencing startup Ultima Genomics said on Tuesday that it will receive an undisclosed investment from Regeneron Pharmaceuticals as the companies collaborate to further develop and test Ultima's second-generation sequencing platform.